Seattle, Washington – March 18, 2025 – Creative Biosciences (Guangzhou) CO., Ltd. (Creative Biosciences), a global leader in non-invasive cancer screening technologies, is proud to announce the opening of its newest branch in Seattle, Washington, USA. This strategic expansion underscores the company’s commitment to making non-invasive early cancer detection more accessible through collaboration with leading healthcare and research institutions in the Americas.

Front desk area

With Seattle’s renowned biotech ecosystem, world-class research centers, and top-tier medical institutions, Creative Biosciences is poised to accelerate the development and adoption of its innovative diagnostic solutions across the Americas markets. The company’s expansion will foster strategic alliances with hospitals, laboratories, and academic institutions, paving the way for groundbreaking advancements in non-invasive early cancer screening.

Dr. Zou & visitors

Dr. Zou meeting visitors

A Commitment to Innovation and Collaboration

For over a decade, Creative Biosciences has been at the forefront of molecular diagnostics, pioneering cutting-edge solutions that improve patient outcomes through early and accurate disease detection. The company’s flagship colorectal cancer screening test, Colosafe, has been widely acknowledged in international markets, earning recognition for its clinical efficacy and ease of use. Its pipeline of early cancer diagnostic tools continues to push the boundaries of precision early cancer detection.  

“The opening of our Seattle branch marks a significant milestone in our global expansion strategy.” said Dr. Hongzhi Zou, CEO and Chairman of Creative Biosciences. “By working closely with esteemed partners and healthcare providers in the Americas, we aim to enhance access to our innovative diagnostic technologies and contribute to the advancement of early cancer detection worldwide.”

Office area

Creative Biosciences’ presence in Seattle will focus on research and development, regulatory advancements, and commercial collaborations, to facilitate the integration of its state-of-the-art diagnostic solutions into the Americas markets. The company remains dedicated to fostering partnerships that will drive scientific innovation and improve patient care on a global scale.

Lab

Creative Biosciences warmly invites investors, partners, researchers, and healthcare professionals to join in its mission to transform cancer diagnostics through innovation and collaboration.

About Creative Biosciences (Guangzhou) CO., Ltd.

Creative Bioscience is a biotechnology pioneer specializing in non-invasive  cancer screening solutions. The company has been dedicated in revolutionizing cancer detection and prevention worldwide. Colosafe is the flagship product providing accurate early detection for colorectal cancer, which has been proven highly effective in large scale population screening and clinical practice. It is the most recommended noninvasive screening test in China. Lunsafe and Urisafe have been successfully developed for noninvasive early detection for lung and bladder cancer respectively. On top of current and future DNA test kits for various types of cancer, the Automatic Sample Preprocessing and Automatic Nucleic Acid Extraction Instruments have been independently invented to accomplish the fully automatic testing process of DNA testing. The HelixPOC Automated Microfluidic Fluorescence PCR System and HemoPOC handheld anticoagulation monitoring system are broadening the product portfolio to enhance diagnostic and self-monitoring anytime and anywhere. By integrating advanced technology with scientific innovation, Creative Biosciences aims to expand access to life-saving diagnostic tools across global markets.

Product display

For partnership inquiries or more information, please visit https://en.Creative Bioscience.cn/ or contact Linda at lindawang@creativebio.com.cn or 1-206-717-2769.